Evidence map›Paper›PMID 37836400›Full record

Trial reportNutrients2023

L-Glutamine and Survival of Patients with Locally Advanced Head and Neck Cancer Receiving Chemoradiotherapy.

Takae Tsujimoto, Masafumi Wasa, Hidenori Inohara, Toshinori Ito

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. The Role of Glutamine Homeostasis in Emotional and Cognitive Functions.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Takae TsujimotoDepartment of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe 650-8586, Japan.ORCID 0000-0001-5402-9712
Masafumi WasaDepartment of Pediatric Surgery, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Osaka 565-0871, Japan.
Hidenori InoharaDepartment of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Osaka 565-0871, Japan.
Toshinori ItoOsaka Center for Cancer & Cardiovascular Disease Prevention, 1-6-107 Morinomiya, Johtou-ku, Osaka 536-0025, Japan.
The University of Osaka · JPKobe Gakuin University · JPOsaka International Cancer Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported that L-glutamine reduces the severity of mucositis caused by chemoradiotherapy in patients with head and neck cancer. However, the impact of glutamine on the anti-tumor effect of chemoradiotherapy remains controversial. This study, which included 40 patients, investigated whether L-glutamine influences survival. Radiation therapy (total: 66 or 70 Gy), cisplatin, and docetaxel were co-administered for a period of 6 weeks. Patients were randomly assigned to receive either glutamine (glutamine group,

Indexed as

GlutamineHead and Neck NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCisplatinDocetaxelHumansCisplatinDocetaxelGlutaminechemoradiotherapyglutathionehead and neck cancerL-glutaminemucositisoral glutamine supplementationoverall response rateoverall survivalprogression-free survivalreactive oxygen species

Identifiers

PMID37836400
PMCPMC10574413
OpenAlexW4386996987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.